<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119037</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0264</org_study_id>
    <secondary_id>NCI-2019-03708</secondary_id>
    <secondary_id>2019-0264</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>R01NR018481</secondary_id>
    <nct_id>NCT04119037</nct_id>
  </id_info>
  <brief_title>Cordotomy in Reducing Pain in Patients With Advanced Cancer</brief_title>
  <official_title>Percutaneous Cordotomy for Pain Palliation in Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well cordotomy works in reducing pain in patients with cancer that has
      spread to other places in the body (advanced). Cordotomy is performed on the spinal cord with
      a needle and guided by computed tomography scans and is designed to help reduce pain. This
      study is being done to learn if a cordotomy reduces pain in patients with unmanageable cancer
      pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the efficacy of cordotomy for patients with unilateral advanced cancer pain.

      SECONDARY OBJECTIVES:

      I. Define the patient experience of cordotomy for cancer pain refractory to palliative care.

      II. Determine whether magnetic resonance imaging (MRI) can be used as a noninvasive biomarker
      for a successful cordotomy.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients undergo a cordotomy over 1-2 hours.

      GROUP II: Patients receive morphine via injection into the spine and undergo a fake cordotomy
      over 1-2 hours.

      After completion of study, patients are followed up at 2 weeks and once every month for up to
      6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in pain intensity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be measured by the Edmonton Symptom Assessment Scale (ESAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory pain interference items</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will provide initial estimates of the magnitude of the effect of cordotomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other ESAS symptoms</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will provide initial estimates of the magnitude of the effect of cordotomy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group I (cordotomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo a cordotomy over 1-2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (morphine, fake cordotomy)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receive morphine via injection into the spine and undergo a fake cordotomy over 1-2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cordotomy</intervention_name>
    <description>Undergo cordotomy</description>
    <arm_group_label>Group I (cordotomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Group II (morphine, fake cordotomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (cordotomy)</arm_group_label>
    <arm_group_label>Group II (morphine, fake cordotomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Intervention</intervention_name>
    <description>Undergo fake cordotomy</description>
    <arm_group_label>Group II (morphine, fake cordotomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Has undergone 3 palliative care evaluations

          -  Pain intensity &gt;= 4 on a 0-10 numerical scale

          -  Unilateral pain due to cancer below the shoulder level (arm, trunk, hip, leg)

        Exclusion Criteria:

          -  Uncorrectable coagulopathy

          -  Large intracranial mass

          -  Inability to complete assessment forms

          -  Life expectancy &lt; 1 month

          -  Contraindication to intravenous sedation

          -  Morphine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashwin Viswanathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashwin Viswanatha</last_name>
    <phone>713-792-6085</phone>
    <email>aviswanathan@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashwin Viswanathan</last_name>
      <phone>713-792-6085</phone>
    </contact>
    <investigator>
      <last_name>Ashwin Viswanathan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

